Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy - Dutour, A.; Abdesselam, I.; Ancel, P.; Kober, F.; Mrad, G.; Darmon, P.; Ronsin, O.; Pradel, V.; Lesavre, N.; Martin, J. C.; Jacquier, A.; Lefur, Y.; et al. (Diabetes, obesity & metabolism, 2016)
Keywords: Adiponectin; Adipose tissue; Adipose Tissue - diagnostic imaging; Adipose Tissue - metabolism; Body fat; Body mass index; Body weight loss; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Endocrinology and metabolism; epicardial adipose tissue; Fatty liver; Fatty Liver - complications; Fatty Liver - diagnostic imaging; Fatty Liver - metabolism; Female; Glucagon; glucagon-like peptide 1 receptor agonist; Glycated Hemoglobin A - metabolism; Heart - diagnostic imaging; Hemoglobin; hepatic triglyceride content; Human health and pathology; Humans; Hypoglycemic Agents - therapeutic use; Insulin resistance; Life Sciences; Liver - diagnostic imaging; Liver - metabolism; Magnetic Resonance Imaging; Magnetic resonance spectroscopy; Male; Middle Aged; myocardial triglyceride content; Myocardium - metabolism; NMR; Nuclear magnetic resonance; Obesity; Obesity - complications; Obesity - metabolism; Pancreas - diagnostic imaging; Pancreas - metabolism; pancreatic triglyceride content; Patients; Peptides - therapeutic use; Pericardium - diagnostic imaging; Pericardium - metabolism; Population studies; Postprandial Period; Proton Magnetic Resonance Spectroscopy; Spectrum analysis; Steatosis; Treatment Outcome; Triglycerides - metabolism; type 2 diabetes; Venoms - therapeutic use; magnetic resonance imaging; type 2 diabetes; hepatic triglyceride content; pancreatic triglyceride content; epicardial adipose tissue; myocardial triglyceride content; proton magnetic resonance spectroscopy; glucagon-like peptide 1 receptor agonist; obesity